Name /I Ju Liu, Ph.D.
Title /Manager and Scientist
Telephone /(Work) 02-27891212#810
AcadeMab Biomedical Inc. established in 2020.
Anti-EpCAM Antibody- Epithelial cell adhesion molecule (EpCAM) is highly expressed on the surface of many different kinds solid tumor which has the potential to become the target of cancer treatment. Our team developed Anti-EpCAM humanized antibody (AM-928) which is able to directly induce cancer cell apoptosis- and inhibit cancer stem cell growth. It has been proven to have obvious treatment in animal models of pancreatic and colorectal cancer, effectively, making AM-928 an unmet medical need for pancreatic and colorectal cancer treatment. The combination of AM-928 with Atezolizumab, an anti-PD-L1 antibody, almost completely eliminated tumors. The AM-928 antibody has been patented in many countries. In order to meet the needs of personalized medicine for anti-EpCAM precision medicine, EpCAM companion diagnostic reagents and molecular imaging are being developed.
Anti-M13 Antibody- The anti-M13 antibody developed by our team has been verified better than the market products and is a powerful tool for the phage display technology.
Anti-HER3 Antibody- Our team developed a fully human anti-HER3 antibody by using phage display technology. After antibody affinity maturation, our anti-HER3 antibody has a potency comparable to the well-known pharmaceutical companies and has great therapeutic potential.
Name /Kalin Chung